Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: Implications for improving outcomes

Clinical Infectious Diseases

Volumn 58, Issue 5, 2014, Pages 736-745

  Jarvis, Joseph N ^a,b,c   Bicanic, Tihana ^a   Loyse, Angela ^a   Namarika, Daniel ^d   Jackson, Arthur ^d   Nussbaum, Jesse C ^d,e   Longley, Nicky ^a,b   Muzoora, Conrad ^f   Phulusa, Jacob ^d   Taseera, Kabanda ^f   Kanyembe, Creto ^d   Wilson, Douglas ^g   Hosseinipour, Mina C ^d   Brouwer, Annemarie E ^h   Limmathurotsakul, Direk ⁱ   White, Nicholas ^i,j   Van Der Horst, Charles ^d   Wood, Robin ^b   Meintjes, Graeme ^b,k   Bradley, John ^c   Jaffar, Shabbar ^c   Harrison, Thomas ^a   more..

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^g EDENDALE HOSPITAL   (South Africa)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ MAHIDOL UNIVERSITY   (Thailand)

^j UNIVERSITY OF OXFORD   (United Kingdom)

^k IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

antiretroviral therapy; cryptococcal meningitis; Cryptococcus neoformans; HIV; mortality (determinants)

Indexed keywords

ADULT; AFRICA; AIDS RELATED COMPLEX; BACTERIAL COUNT; CEREBROSPINAL FLUID; COHORT ANALYSIS; COMPLICATION; CRYPTOCOCCAL MENINGITIS; FEMALE; HIV INFECTIONS; HUMAN; IMMUNOLOGY; LONGITUDINAL STUDY; MALE; MENTAL DISORDERS; MICROBIOLOGY; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY; RISK FACTOR; THAILAND;

ADULT; AFRICA; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CEREBROSPINAL FLUID; COHORT STUDIES; COLONY COUNT, MICROBIAL; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MENINGITIS, CRYPTOCOCCAL; MENTAL DISORDERS; PROSPECTIVE STUDIES; RISK FACTORS; THAILAND;

EID: 84894235223     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit794     Document Type: Article

References (31)

1. Jarvis JN, Meintjes G, Williams A, Brown Y, Crede T, Harrison TS. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis 2010; 10:67.
2. Scarborough M, Gordon SB, Whitty CJ, et al. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J Med 2007; 357:2441-50.
3. Hakim JG, Gangaidzo IT, Heyderman RS, et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients. AIDS 2000; 14:1401-7.
4. Bekondi C, Bernede C, Passone N, et al. Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. Int J Infect Dis 2006; 10:387-95.
5. Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008; 47:123-30.
6. Jarvis JN, Meintjes G, Harrison TS. Outcomes of cryptococcal meningitis in antiretroviral naive and experienced patients in South Africa. J Infect 2010; 60:496-8.
7. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008; 46:1694-701.
8. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcalmeningitis among persons living with HIV/AIDS. AIDS 2009; 23:525-30.
9. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363:1764-7.
10. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007; 45:76-80.
11. Longley N, Muzoora C, Taseera K, et al. Dose response effect of highdose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 2008; 47:1556-61.
12. Nussbaum JC, Jackson A, Namarika D, et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis 2009; 50:338-44.
13. Loyse A, Wilson D, Meintjes G, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as secondline drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2011; 54:121-8.
14. Muzoora CK, Kabanda T, Ortu G, et al. Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. J Infect 2011; 64:76-81.
15. Jackson A, NussbaumJ, Phulusa J, et al. A phase II randomised controlled trial adding oral flucytosine to high dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis in Malawi. AIDS 2012; 26: 1363-70.
16. Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 2012; 26:1105-13.
17. Bicanic T, Muzoora C, Brouwer AE, et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 2009; 49:702-9.
18. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:291-322.
19. Siddiqui AA, Brouwer AE, Wuthiekanun V, et al. IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol 2005; 174:1746-50.
20. Bicanic T, Meintjes G, Rebe K, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr 2009; 51:130-4.
21. May M, Boulle A, Phiri S, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 2010; 376:449-57.
22. Jarvis JN, Casazza JP, Stone HH, et al. The phenotype of the cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis. J Infect Dis 2013; 207:1817-28.
23. Wijewardana I, Jarvis JN, Meintjes G, Harrison TS, Bicanic T. Large volume lumbar punctures in cryptococcal meningitis clear cryptococcal antigen as well as lowering pressure. J Infect 2011; 63:484-6.
24. Jarvis JN, Percival A, Bauman S, et al. Evaluation of a novel pointof-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 2011; 53:1019-23.
25. Lindsley MD, Mekha N, Baggett HC, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis 2011; 53:321-5.
26. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009; 48:856-62.
27. Meya DB, Manabe YC, Castelnuovo B, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count
28. Jarvis JN, Lawn SD, Wood R, Harrison TS. Cryptococcal antigen screening for patients initiating antiretroviral therapy: time for action. Clin Infect Dis 2010; 51:1463-5.
29. World Health Organization. Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. December 2011. Available at: http://www.who.int/hiv/pub/cryptococcal- disease2011/en/. Accessed 26 August 2013.
30. Loyse A, Bicanic T, Jarvis JN. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 2013; 368:2522.
31. Loyse A, Thangaraj H, Easterbrook P, et al. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis 2013; 13:629-37.